JO3442B1 - مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) - Google Patents

مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)

Info

Publication number
JO3442B1
JO3442B1 JOP/2014/0283A JOP20140283A JO3442B1 JO 3442 B1 JO3442 B1 JO 3442B1 JO P20140283 A JOP20140283 A JO P20140283A JO 3442 B1 JO3442 B1 JO 3442B1
Authority
JO
Jordan
Prior art keywords
sstr5
antagonists
compound
receptor subtype
somatostatin receptor
Prior art date
Application number
JOP/2014/0283A
Other languages
English (en)
Inventor
Shizuo Kasai
Hideki Hirose
Asato Kina
Tohru Yamashita
Yoichi Nishikawa
Takeshi Yamasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3442B1 publication Critical patent/JO3442B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<strong>يتعلق الاختراع الحالي بتوفير مركب له فعل مضاد </strong><span dir="LTR">SSTR5</span><strong> واستخدام المركب كدواء. على وجه التحديد، مركب يتم التعبير عنه بواسطة الصيغة التالية:</strong> <span dir="LTR"><img alt="??????? PT38-0003 ?????? 2013-20982620131007----00850075251302101257??20131007102827201310071027595150__________PT_84" src="file:///C:/Users/Darwish.Q/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /></span> <strong>حيث يكون كل رمز كما تم التحديد في هذه الوثيقة،</strong> <strong> أو ملح منه، ويتم توفير دواء يشتمل على المركب أو ملح منه، واستخدام المركب أو ملح منه كعامل للوقاية من أو علاج مرض السكر. </strong>
JOP/2014/0283A 2013-10-07 2014-10-02 مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) JO3442B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013209826 2013-10-07

Publications (1)

Publication Number Publication Date
JO3442B1 true JO3442B1 (ar) 2019-10-20

Family

ID=51842719

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0283A JO3442B1 (ar) 2013-10-07 2014-10-02 مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)

Country Status (24)

Country Link
US (2) US9353108B2 (ar)
EP (1) EP3055309B1 (ar)
JP (1) JP6411520B2 (ar)
CN (1) CN105612158B (ar)
AR (1) AR097932A1 (ar)
BR (1) BR112016007620B1 (ar)
CA (1) CA2926544C (ar)
CY (1) CY1121163T1 (ar)
DK (1) DK3055309T3 (ar)
ES (1) ES2687102T3 (ar)
HR (1) HRP20181372T1 (ar)
HU (1) HUE039386T2 (ar)
JO (1) JO3442B1 (ar)
LT (1) LT3055309T (ar)
PL (1) PL3055309T3 (ar)
PT (1) PT3055309T (ar)
RS (1) RS57743B1 (ar)
RU (1) RU2671958C2 (ar)
SI (1) SI3055309T1 (ar)
SM (1) SMT201800461T1 (ar)
TR (1) TR201810506T4 (ar)
TW (1) TWI648276B (ar)
UY (1) UY35774A (ar)
WO (1) WO2015052910A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6247697B2 (ja) * 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
CN107001332B (zh) * 2014-12-02 2020-05-15 豪夫迈·罗氏有限公司 哌啶衍生物
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
WO2021230264A1 (ja) * 2020-05-13 2021-11-18 株式会社スコヒアファーマ 胆道系疾患の診断補助・予防・治療剤
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
JP2025519195A (ja) * 2022-05-30 2025-06-24 賽諾哈勃薬業（成都）有限公司 癒着関連疾患を予防・治療する薬物の調製におけるテトラヒドロナフチリヂン誘導体の使用
KR20250157553A (ko) 2023-03-27 2025-11-04 가부시키가이샤 스코히아 파마 성장 호르몬 분비 촉진제

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
JP2005504100A (ja) 2001-09-24 2005-02-10 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の治療のための１，５，６，７−テトラヒドロピロロ［３，２−ｃ］ピリジン誘導体の製造法および使用
KR20040041177A (ko) * 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
PL376733A1 (pl) 2002-11-01 2006-01-09 Takeda Pharmaceutical Company Limited Środek do zapobiegania lub leczenia neuropatii
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
AU2004289690A1 (en) 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as CCR-5 antagonists
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
CA2617969A1 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
ES2379661T3 (es) 2006-06-27 2012-04-30 Takeda Pharmaceutical Company Limited Compuestos cíclicos condensados
MX2009001498A (es) * 2006-08-15 2009-02-18 Hoffmann La Roche Derivados de fenilo, piridina y quinolina.
JP5306818B2 (ja) 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
CA2677736A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) * 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
TW200918062A (en) 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
WO2010129729A1 (en) 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
EP2605658B1 (en) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
CA2818050A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
JP6247697B2 (ja) 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
SI3063139T1 (sl) 2013-10-29 2019-03-29 Takeda Pharmaceutical Company Limited Heterociklična spojina

Also Published As

Publication number Publication date
US9751878B2 (en) 2017-09-05
TR201810506T4 (tr) 2018-08-27
ES2687102T3 (es) 2018-10-23
TWI648276B (zh) 2019-01-21
CA2926544A1 (en) 2015-04-16
JP2016531950A (ja) 2016-10-13
JP6411520B2 (ja) 2018-10-24
HUE039386T2 (hu) 2018-12-28
PT3055309T (pt) 2018-10-01
HRP20181372T1 (hr) 2018-10-19
US20150099777A1 (en) 2015-04-09
US9353108B2 (en) 2016-05-31
RU2671958C2 (ru) 2018-11-08
PL3055309T3 (pl) 2018-10-31
RS57743B1 (sr) 2018-12-31
LT3055309T (lt) 2018-08-27
CA2926544C (en) 2021-07-06
US20160237087A1 (en) 2016-08-18
AR097932A1 (es) 2016-04-20
SI3055309T1 (sl) 2018-10-30
BR112016007620A2 (pt) 2017-08-01
RU2016117732A (ru) 2017-11-15
CN105612158B (zh) 2017-06-30
EP3055309A1 (en) 2016-08-17
DK3055309T3 (en) 2018-08-27
CY1121163T1 (el) 2020-05-29
WO2015052910A1 (en) 2015-04-16
BR112016007620B1 (pt) 2020-05-26
CN105612158A (zh) 2016-05-25
EP3055309B1 (en) 2018-06-13
TW201536784A (zh) 2015-10-01
SMT201800461T1 (it) 2018-11-09
UY35774A (es) 2015-05-29

Similar Documents

Publication Publication Date Title
JO3442B1 (ar) مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
PH12016501582A1 (en) Fused heterocyclic compound
PH12016501614A1 (en) Heterocyclic compound
MX2019010531A (es) Compuesto peptidico.
PH12014502857A1 (en) Analogs of glucagon exhibiting gip receptor activity
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MX2014015558A (es) Analogos de glucagon que exhiben actividad del receptor gip.
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
JO3452B1 (ar) بنزاميدات أمينو اريل مغاير كمثبطات كيناز
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX2016004088A (es) Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo.
TN2016000567A1 (en) Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
MY152946A (en) Fused ring compound and use thereof
EA201370149A1 (ru) Антагонисты рецептора
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
EA201591645A1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре
PH12015502703A1 (en) Pharmaceutical compositions
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
UA86566U (en) N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof
IN2013MU02610A (ar)
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями
PL405987A1 (pl) Zastosowanie skrobi rozpuszczalnej